Loading clinical trials...
Loading clinical trials...
A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Altoona, Pennsylvania, United States
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Moron- Buenos Aires, Argentina
Research Sites
Quilmes - Buenos Aires, Argentina
Research Site
Rosario, Argentina
Research Site
Salta, Argentina
Research Site
Curitiba, Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Abbotsford, British Columbia, Canada
Start Date
August 1, 2004
Primary Completion Date
October 1, 2006
Completion Date
October 1, 2006
Last Updated
November 19, 2010
1,450
Estimated participants
Galida
DRUG
Lead Sponsor
AstraZeneca
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062